Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of 5-grass pollen SLIT tablets for grass pollen rhinoconjunctivitis
2005-002501-23Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Sep 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing 5-grass pollen allergen extract SLIT tablet with Placebo (2 arms). Primary endpoints: Average Rhinoconjunctivitis Total Symptom Score during the third pollen period and Average Rhinoconjunctivitis Total Symptom Score during the fourth pollen period. Started Sep 2005; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2005-002501-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002501-23.